Genetics of Minoxidil Response

Minoxidil is a medication used for the treatment of hair loss. It was initially developed as an oral medication to treat high blood pressure (hypertension), but during clinical trials, it was found to have an interesting side effect — promoting hair growth. Since then, it has been extensively studied and is now primarily used as a topical treatment for androgenetic alopecia (male-pattern baldness and female-pattern baldness).

Here are some key points about minoxidil in the treatment of hair loss:

How Minoxidil Works:

  • Dilation of Blood Vessels: Minoxidil is thought to work by dilating blood vessels in the scalp. This may improve hair follicle function and stimulate hair growth.
  • Prolonging Growth Phase: It may also prolong the growth phase of hair follicles (anagen phase), which can lead to increased hair thickness and length.
  • Unknown Mechanism: Despite its widespread use, the exact mechanism by which minoxidil promotes hair growth is not fully understood.


  • Male-Pattern Baldness: In men with male-pattern baldness, minoxidil has been shown to promote hair regrowth in some individuals. It’s most effective in those who have recently started to lose their hair.
  • Female-Pattern Baldness: It is also FDA-approved for use in women with female-pattern baldness, which usually causes diffuse thinning on the top of the head. Women may see improvement in hair thickness and coverage.


  • Topical Application: Minoxidil is usually applied topically to the scalp in either liquid or foam form. It needs to be applied consistently, typically twice a day.
  • Drying Time: After applying, it’s important to allow the solution to dry completely before going to bed or wearing a hat or other head coverings.

Side Effects:

  • Scalp Irritation: Some people experience mild scalp irritation, such as itching or redness, especially when first using the product.
  • Unwanted Hair Growth: There is a risk of unwanted hair growth on other parts of the body where the medication comes into contact. This is more common with the 5% solution compared to the 2% solution.
  • Heart Effects: Since it was initially a medication for hypertension, there is a theoretical risk of cardiovascular effects, although these are rare with topical use.

Important Considerations:

  • Consistency: Minoxidil must be used continuously to maintain hair growth. If you stop using it, any hair gained will likely be lost within a few months to a year.
  •  Results Vary: Results can vary from person to person. Some may see significant regrowth, while others may see minimal to no improvement.
  • Combination Therapy: It can be used in combination with other hair loss treatments, such as finasteride, for enhanced results.

Before starting minoxidil or any hair loss treatment, it’s a good idea to consult with a healthcare professional, such as a dermatologist. They can provide guidance on whether minoxidil is appropriate for your type of hair loss and any potential side effects or interactions with other medications.

Minoxidil can elicit different responses in different individuals. Here’s how people may respond to minoxidil:

  • Positive Response: Many individuals experience positive results with minoxidil. They may notice new hair growth, thicker hair, and a slowing down or halting of hair loss. These effects can vary in timing and degree from person to person.
  • Limited Response: Some people may find that minoxidil has limited effectiveness for them. While they may experience some improvement, it might not meet their expectations or significantly address their hair loss concerns.
  • Adverse Reactions: A minority of individuals may experience adverse reactions to minoxidil. These can include scalp irritation, itching, redness, or a rash. In some cases, individuals may also experience unwanted hair growth in areas other than the scalp.
  • Non-Responders: There are individuals who do not respond to minoxidil at all. Despite consistent and proper application, they may not see any noticeable improvement in their hair loss condition.
  • Initial Shedding: Some individuals may experience an initial shedding phase when they start using minoxidil. This shedding is often temporary and is believed to be part of the hair growth cycle. New hair growth typically follows this shedding phase.
  • Long-Term Use: Continuous and consistent use of minoxidil is often required to maintain its benefits. If usage is discontinued, any hair regrowth achieved through minoxidil may gradually diminish, and hair loss may resume.
  • Combination Therapy: Minoxidil is often used in combination with other hair loss treatments, such as finasteride or certain shampoos, for enhanced efficacy.

It’s important for individuals using minoxidil to understand that results can vary widely among users, and it may take several months of consistent use to see noticeable improvements. Additionally, consulting with a healthcare professional before starting any hair loss treatment regimen is recommended to ensure its suitability and to discuss any potential side effects or concerns.

Minoxidil is a medication used to treat hair loss, and SULT1A1 is an enzyme involved in the metabolism of various drugs, including minoxidil. Understanding the pharmacogenetics of SULT1A1 in relation to minoxidil can provide insights into how genetic variations may affect an individual’s response to the drug.

SULT1A1 and Minoxidil Metabolism

  • SULT1A1: This enzyme is part of the sulfotransferase family and is primarily involved in the metabolism of various endogenous and exogenous compounds, including drugs. It catalyzes the sulfation of minoxidil.
  • Minoxidil Metabolism: Minoxidil itself is not active but is metabolized in the liver to its active form, minoxidil sulfate. This active form is responsible for the drug’s vasodilatory effects, which contribute to its effectiveness in treating hair loss.

Genetic Variations in SULT1A1

Genetic variations in the SULT1A1 gene can influence the activity of the enzyme, potentially affecting how individuals metabolize minoxidil. Some research suggests that certain variants of the SULT1A1 gene may lead to:

  • Increased Activity: Some variants may increase the activity of SULT1A1, resulting in more rapid conversion of minoxidil to its active form. This could potentially lead to a stronger response to minoxidil treatment but might also increase the risk of side effects.
  • Decreased Activity: Conversely, other variants may decrease SULT1A1 activity, leading to slower metabolism of minoxidil. This might result in a weaker response to the drug or a need for higher doses to achieve the desired effect.

Clinical Implications

  • Efficacy: Individuals with certain genetic variants that increase SULT1A1 activity may respond better to standard doses of minoxidil. On the other hand, those with reduced SULT1A1 activity might require higher doses for the drug to be effective.
  • Side Effects: Higher SULT1A1 activity could potentially lead to increased side effects, such as hypotension (low blood pressure) due to the increased production of minoxidil sulfate. Monitoring for adverse reactions may be particularly important in individuals with these genetic variants.

Personalized Medicine

Understanding the pharmacogenetics of SULT1A1 in the context of minoxidil use can contribute to the field of personalized medicine. By identifying a patient’s specific genetic profile, doctors may be able to:

  • Optimize Dosing: Tailor minoxidil doses based on an individual’s genetic makeup to achieve the desired therapeutic effect.
  • Predict Response: Predict how individuals are likely to respond to minoxidil, guiding treatment decisions and potentially improving outcomes.

Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review.

Pietrauszka K, Bergler-Czop B.Postepy Dermatol Alergol. 2022 Jun;39(3):472-478. doi: 10.5114/ada.2020.99947. Epub 2020 Oct 16.PMID: 35950120 

Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss.

Ramos PM, Gohad P, McCoy J, Wambier C, Goren A.J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e24-e26. doi: 10.1111/jdv.16765. Epub 2020 Jul 9.PMID: 32567076 

A review of the treatment of male pattern hair loss.

York K, Meah N, Bhoyrul B, Sinclair R.Expert Opin Pharmacother. 2020 Apr;21(5):603-612. doi: 10.1080/14656566.2020.1721463. Epub 2020 Feb 17.PMID: 32066284 

Role of Oral Minoxidil in Patterned Hair Loss.

Ramírez-Marín HA, Tosti A.Indian Dermatol Online J. 2022 Oct 12;13(6):729-733. doi: 10.4103/idoj.idoj_246_22. eCollection 2022 Nov-Dec.PMID: 36386734 

Minoxidil: mechanisms of action on hair growth.

Messenger AG, Rundegren J.Br J Dermatol. 2004 Feb;150(2):186-94. doi: 10.1111/j.1365-2133.2004.05785.x.PMID: 14996087 

SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth.

Dhurat R, Daruwalla S, Pai S, Kovacevic M, McCoy J, Shapiro J, Sinclair R, Vano-Galvan S, Goren A.J Cosmet Dermatol. 2022 Jan;21(1):343-346. doi: 10.1111/jocd.14299. Epub 2021 Jun 25.PMID: 34133836 

Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients.

Ramos PM, Sinclair R, Miot HA, Goren A.Dermatol Ther. 2020 Jan;33(1):e13195. doi: 10.1111/dth.13195. Epub 2019 Dec 27.PMID: 31846181 

Clinical utility and validity of minoxidil response testing in androgenetic alopecia.

Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, Pietrzak A, Lotti T.Dermatol Ther. 2015 Jan-Feb;28(1):13-6. doi: 10.1111/dth.12164. Epub 2014 Aug 12.PMID: 25112173

Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data.

Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Moreno-Arrones OM, Ortega-Quijano D, Fernandez-Nieto D, Jaen-Olasolo P, Vaño-Galvan S.Dermatol Ther. 2020 Nov;33(6):e14106. doi: 10.1111/dth.14106. Epub 2020 Sep 7.PMID: 32757405

Dose-response study of topical minoxidil in male pattern alopecia.

Shupack JL, Kassimir JJ, Thirumoorthy T, Reed ML, Jondreau L.J Am Acad Dermatol. 1987 Mar;16(3 Pt 2):673-6. doi: 10.1016/s0190-9622(87)70086-3.PMID: 3549801